Actively Recruiting
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Led by Australia and New Zealand Sarcoma Association · Updated on 2026-01-30
100
Participants Needed
9
Research Sites
429 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.
CONDITIONS
Official Title
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older with first recurrent well-differentiated and/or dedifferentiated liposarcoma of the retroperitoneal space or pelvis after previous complete or near-complete surgery
- No distant metastasis confirmed by chest, abdomen, and pelvis imaging within 1 month
- Histologically confirmed well-differentiated or dedifferentiated liposarcoma only
- Sarcoma not originating from bone, abdominal, or gynecological organs
- Tumor must be deemed resectable with expected complete or near-complete removal and treatable by radiation therapy as confirmed by a multidisciplinary team
- WHO performance status of 0 to 2
- American Society of Anaesthesiologist (ASA) score of 1 to 3
- No previous radiation therapy for retroperitoneal liposarcoma
- Prior systemic therapy is allowed
- No active concurrent malignancy except low-risk skin, prostate, or breast cancers including in situ
- Women of childbearing potential must have a negative pregnancy test within 3 weeks before treatment
- Able to comply with study requirements as judged by the investigator
- Signed informed consent approved by the institutional review board
You will not qualify if you...
- Tumor is unresectable or likely to have incomplete removal as assessed by the multidisciplinary sarcoma team
- Extent of recurrence prevents feasible preoperative radiation therapy to all visible disease
- Contraindications to radiation therapy such as history of bowel obstruction, mesenteric ischemia, or severe chronic inflammatory bowel disease
- Myxoid liposarcoma histology
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Emory Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Actively Recruiting
2
OSU James Hospital
Columbus, Ohio, United States, 43210
Not Yet Recruiting
3
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
4
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia, 2050
Actively Recruiting
5
Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
Actively Recruiting
6
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3000
Actively Recruiting
7
UZ Leuven
Leuven, Flemish Brabant, Belgium, 3000
Actively Recruiting
8
A.C.Camargo Cancer Center - Fundacao Antonio Prudente
Liberdade, São Paulo, Brazil, 01509-010
Actively Recruiting
9
The Netherlands Cancer Institute
Amsterdam, North Holland, Netherlands, 1066 CX
Actively Recruiting
Research Team
J
Janina Chapman
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here